Targeting the Cell Surfaceome of Aggressive Neuroendocrine Prostate Cancer
Technical Report,01 Jul 2017,30 Jun 2018
University of California Los Angeles United States
Pagination or Media Count:
In this reporting period, we have performed transcriptomic and cell surface proteomic profiling of a panel of human prostate cancer cell lines and integrated these data sets to nominate high-confidence cell surface antigens associated with neuroendocrine prostate cancerNEPC and prostate adenocarcinoma PrAd. Validation of candidate antigens is ongoing but several have demonstrated prostate cancer subtype-specific protein expression based on immunoblotting, immunohistochemistry, and flow cytometry of prostate cancer cell lines, xenografts, and clinical prostate cancer tissues. For example, we have characterized CEACAM5carcinoembryonic antigen 5 as a cell surface marker expressed in 60 of NEPC but not inPrAd. This finding has led to new projects in the laboratory with potential for clinical translation related to therapeutically targeting CEACAM5-positive NEPC with an antibody-drug conjugate or chimeric antigen receptor T cell immunotherapy.
- Medicine and Medical Research